CoDa Therapeutics Completes $49 Million Fund Raising
24 July 2012
CoDa Therapeutics, Inc. announced today that it raised an additional NZ$24.5M from Russian investment firm RusnanoMedInvest (“RMI”). This brings the company’s total Series B Round to nearly NZ$49 million following a first close late last year.
Square 1 Announces $6 Million Credit Facility to CoDa Therapeutics, Inc.
06 October 2011
Square 1 Bank, the exclusive banking partner to entrepreneurs and the venture capital community, is pleased to partner with CoDa Therapeutics, Inc. in providing a $6 million term loan.
Marinus Pharmaceuticals Issued Patent for Ganaxolone
29 April 2011
Marinus Pharmaceuticals, Inc., the leader in development of neurosteroids for central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) issued the company Patent Number 7,858,609 entitled, "Solid ganaxolone formulations and methods for the making and use thereof." The patent describes a novel class of small molecules to improve stability and bioavailability of nanoparticulate formulations of ganaxolone and will provide coverage until the end of 2026.
CoDa Therapeutics, Inc. announced that it has raised $19.2 million in a Series B financing.
18 April 2011
San Diego, California - April 18, 2011 - CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing.
17 April 2011
Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced the award of a $3 million grant by the U.S. Department of Defense to study its lead candidate ganaxolone for the treatment of Fragile-X Syndrome (FXS). Ganaxolone modulates GABA-A ion channels by selective binding to the neurosteroid receptor. Early research suggests that normalizing neurosteroid levels with ganaxolone treatment may eliminate the behavioral symptoms associated with FXS.
Merry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
2024 drug approvals: Small companies loom large with several key FDA nods
13 January 2025
Special Regulations for Foreign-Packaged Medicines Extended Until the End of 2025
13 January 2025
Russia Begins Production of Terbium-161 Isotope for Cancer Therapy
10 January 2025
FMBA has begun clinical trials of a vaccine against five serotypes of meningococcus
10 January 2025